Core Viewpoint - The company reported significant growth in its pig farming business for December 2025, indicating a positive trend in sales and inventory levels [1]. Group 1: Key Operational Data - In December 2025, the company sold 162,300 pigs, representing a year-on-year increase of 28.39% and a month-on-month increase of 2.92% [1]. - As of the end of December 2025, the company's pig inventory stood at 743,400 heads, which is an increase of 44.92% compared to the end of December 2024 and a 6.24% increase from the end of November 2025 [1]. Group 2: Strategic Focus - The company is actively optimizing its pig farming capacity by adjusting its farming layout, scale, and breed structure, while continuing to focus on cost reduction and resource concentration to develop competitive capacity [1]. - The company emphasizes a pragmatic approach to its operational goals, aiming for steady progress and ongoing cost reduction initiatives [1].

证券代码：603363 证券简称：傲农生物 公告编号：2026-001 福建傲农生物科技集团股份有限公司 2025 年 12 月养殖业务主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 福建傲农生物科技集团股份有限公司（以下简称"公司"）现将 2025 年 12 月养殖业务主要经营数据披露如下： 2025 年 12 月，公司生猪销售量 16.23 万头，同比增加 28.39%，较 2025 年 11 月增加 2.92%。 2025 年 12 月末，公司生猪存栏 74.34 万头，较 2024 年 12 月末增加 44.92%， 较 2025 年 11 月末增加 6.24%。 公司积极推动生猪养殖产能优化工作，合理调整养殖布局、规模与品种结构， 后续将继续坚持"稳字当头、持续降本"的策略，集中资源发展优势产能，务实 经营发展目标，切实推进降本工作。 二、其他说明 本次披露的 2025 年 12 月养殖经营数据来自公司内部统计，未经审计，仅供 投资者及时了解本公司养殖业务生产经营概况，未对公司未来经营情况作出任何 ...

傲农生物（603363）(603363.SH)发布公告，2025年12月，公司生猪销售量16.23万头，同比增加 28.39%，较2025年11月增加2.92%。2025年12月末，公司生猪存栏74.34万头，较2024年12月末增加 44.92%，较2025年11月末增加6.24%。 ...

智通财经APP讯，傲农生物(603363.SH)发布公告，2025年12月，公司生猪销售量16.23万头，同比增加 28.39%，较2025年11月增加2.92%。2025年12月末，公司生猪存栏74.34万头，较2024年12月末增加 44.92%，较2025年11月末增加6.24%。 ...

公司积极推动生猪养殖产能优化工作，合理调整养殖布局、规模与品种结构，后续将继续坚持"稳字当 头、持续降本"的策略，集中资源发展优势产能，务实经营发展目标，切实推进降本工作。 格隆汇1月7日丨傲农生物（维权）(603363.SH)公布，2025年12月，公司生猪销售量16.23万头，同比增 加28.39%，较2025年11月增加2.92%。2025年12月末，公司生猪存栏74.34万头，较2024年12月末增加 44.92%，较2025年11月末增加6.24%。 ...

Core Viewpoint - Aonong Biological (603363.SH) reported a significant increase in pig sales and inventory, indicating a positive growth trend in its operations and a focus on optimizing production capacity [1] Group 1: Sales Performance - In December 2025, the company sold 162,300 pigs, representing a year-on-year increase of 28.39% and a month-on-month increase of 2.92% [1] Group 2: Inventory Levels - As of the end of December 2025, the company's pig inventory stood at 743,400 heads, which is a 44.92% increase compared to the end of December 2024 and a 6.24% increase from the end of November 2025 [1] Group 3: Strategic Focus - The company is actively promoting the optimization of pig farming capacity by adjusting breeding layout, scale, and breed structure, while continuing to adhere to a strategy focused on stability and cost reduction [1] - The company aims to concentrate resources on developing advantageous production capacity and pragmatically pursue operational development goals [1]

人民财讯1月7日电，傲农生物（603363）1月7日发布2025年12月养殖业务主要经营数据公告，2025年12 月，公司生猪销售量16.23万头，同比增加28.39%，较2025年11月增加2.92%。2025年12月末，公司生猪 存栏74.34万头，较2024年12月末增加44.92%，较2025年11月末增加6.24%。 ...

格隆汇1月7日｜傲农生物（维权）公告，公司2025年12月生猪销售量16.23万头，同比增加28.39%，较 2025年11月增加2.92%；月末生猪存栏74.34万头，同比增加44.92%，较2025年11月末增加6.24%。2025 年1—12月生猪累计销售量175.07万头。 ...

Market Overview - The feed sector experienced a decline of 1.08% on December 31, with TianKang Biological leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Individual Stock Performance - JinXinNong (002548) saw a significant increase of 9.95%, closing at 6.08, with a trading volume of 816,900 shares and a transaction value of 479 million [1] - TianKang Biological (002100) declined by 3.03%, closing at 7.37, with a trading volume of 337,500 shares and a transaction value of 250 million [2] - Other notable performers include ZhiYang Co. (002696) with a 1.00% increase, and Boen Group (001366) with a 0.91% increase [1] Capital Flow Analysis - The feed sector experienced a net outflow of 75.87 million from institutional investors, while retail investors saw a net inflow of 22.40 million [2] - JinXinNong had a net inflow of 64.54 million from institutional investors, but a net outflow of 36.08 million from retail investors [3] - TianMa Technology (603668) had a net inflow of 11.83 million from institutional investors, while retail investors experienced a net outflow of 13.32 million [3]

Core Viewpoint - The report outlines the changes in shareholding structure of Fujian Aonong Biological Technology Group Co., Ltd. due to the expiration of the "Joint Action Agreement" among the information disclosing parties, leading to the individual calculation of their respective shareholdings [1][5]. Group 1: Shareholding Changes - The information disclosing parties collectively held 208 million shares, accounting for 7.99% of the total share capital before the expiration of the agreement [7]. - After the expiration of the agreement on December 27, 2025, the shareholdings will be calculated separately: China Foreign Economic and Trade Trust holds 65 million shares (2.4972%), Xiamen International Trust holds 123 million shares (4.7254%), and Beijing Yawen holds 20 million shares (0.7684%) [8]. - Following the expiration, none of the information disclosing parties will be considered as shareholders holding more than 5% of the company [8]. Group 2: Purpose of the Equity Change - The purpose of the equity change is due to the termination of the "Joint Action Agreement," which does not involve any change in the number of shares held by the information disclosing parties [5]. - The parties plan to reduce their holdings in Aonong Biological shares within the next 12 months based on their actual circumstances after the termination of the joint action relationship [5][6]. Group 3: Compliance and Disclosure - The report confirms that the information disclosing parties have obtained necessary authorizations and approvals for the report, ensuring compliance with relevant laws and regulations [2]. - There are no restrictions on the rights associated with the shares held by the information disclosing parties as of the report's signing date [9].